BIOLIDICS (8YY) on Monday said it has developed a new ClearEpi NAB Test product which detects an individual's protective immunity against Covid-19.

THE following companies saw new developments that may affect trading of their securities on Tuesday:

SHARES of Catalist-listed medical technology (medtech) players Biolidics and Medtecs International fell on Monday morning, after both companies announced their H1 financial results on Friday following the close of trading.

MEDTECH company Biolidics 8YY posted a S$3 million loss for the six months ended June 2021 - widening from the S$0.1 million loss in the year-ago period - amid a "highly competitive market" with a growing supply of antigen and antibody test kits.

CATALIST-LISTED medtech firm Biolidics on Monday reached an "amicable settlement" with Japan biochip partner Sysmex Corporation "without any admission to liability", putting paid to previous disputes over intellectual property (IP).

Biolidics has received product authorisation from Indonesia’s ministry of health for the usage and distribution of the company’s ClearEpi SARS-CoV-2 Antigen Rapid Test Kit (ClearEpi ART) in Indonesia.  In a filing to SGX dated March 15, the company states that the authorisation remains vali...

MEDTECH firm Biolidics on Monday launched a Covid-19 antigen test kit which can be marketed and sold in the European Union (EU).

In an unrated note published in a question and answer format on Dec 14, PhillipCapital’s research team spoke to Biolidics on the company’s recent developments on its SARS-CoV-2 Antigen Rapid Test Kit and other Covid-19 test kits. In March 2020, the Singapore-based medical technology company laun...

SHARES in Catalist-listed Biolidics rallied for a third consecutive day on Friday, advancing more than 20 per cent by the closing bell.

SHARES in Catalist-listed Biolidics rallied for a third consecutive day on Friday, advancing more than 20 per cent by the afternoon trade.